Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZP-025 (Monurelle Biogel) is a non-hormonal vaginal gel containing purified, dialyzed, and lyophilized bovine colostrum. It is indicated for the treatment of vaginal dryness and symptoms associated with vaginal atrophy in both post-menopausal women and women of reproductive age. The bovine colostrum component is rich in bioactive molecules, including growth factors and immunoglobulins, which work to restore the physiological thickness of the vaginal epithelium and improve local blood flow (vascular capacitance). Clinical trials have shown that ZP-025 significantly improves vaginal health index (VHI) scores and sexual function, providing a safe alternative to hormone replacement therapy for local symptoms. It is regulated as a medical device in the European Union.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Monurelle Biogel.